In this issue of Blood, Lin et al elegantly demonstrate that the erythrocytes from patients with paroxysmal nocturnal hemoglobinuria (PNH) undergoing eculizumab treatment, which are opsonized with the complement C3dg, can interact with complement receptor 3 (CR3) on activated monocytes, thus leading to erythrophagocytosis.